An interventional study of Tangible Boost and Placebo in Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye and Sjogren's Syndrome, sponsored by Tangible Science. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Tangible Science · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Stevens-Johnson Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Stevens-Johnson Syndrome · United States.
Among the 11 studies in Stevens-Johnson Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 3 with no phase, and was the 9th registered.
40 studies on the registry are indexed under Stevens-Johnson Syndrome; 7 are open to participants now.
Browse Stevens-Johnson Syndrome studies →1 of the 11 studies in Stevens-Johnson Syndrome with a site in United States is open now. Recruiting first, the newest first:
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Stevens-Johnson Syndrome studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 2
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is above the median of 20 across 24 interventional studies indexed under Stevens-Johnson Syndrome.
Median enrollment 1 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 9 most frequent:
Tangible Science is the lead sponsor of 3 studies on the registry; none are open to participants now.
Tangible Science has 1 study filed under Stevens-Johnson Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Stevens-Johnson Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06926478Massachusetts Eye and Ear InfirmarySubconjunctival Humira for Boston Keratoprosthesis | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Stevens-Johnson Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
Hydra-PEG is a coating for soft and rigid contact lens, primarily composed of polyethylene glycol-based hydrogel, which is covalently bound to the surface of a contact lens. The Hydra-PEG coating is intended to improve wettability and comfort with contact lenses and is currently FDA approved on a number of contact lenses. For patients with Stevens Johnson Syndrome (SJS) (SS), or Graft versus Host disease (GVHD), diminished efficacy of the Hydra-PEG coating can lead to significant decline in satisfaction with the lenses over time. This is a prospective study to evaluate the efficacy of Tangible Boost, a monthly conditioning solution, to replenish the Hydra-PEG coating on rigid gas permeable contact lenses for patients with SJS, GVHD, and SS. Outcomes from this patient population will be compared to patients with dry eye disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.
Device: Tangible Boost
Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.
Other: Placebo
Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
Visual Acuity
LogMAR visual acuity
Time frame: 3 months
Visual Acuity
LogMAR visual acuity
Time frame: 6 months
Contact Lens Comfort
OSDI plus additional specific questions
Time frame: 3 months
Contact Lens Comfort
OSDI plus additional specific questions
Time frame: 6 months
Ocular Surface Staining
Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.
Time frame: 3 months
Ocular Surface Staining
Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.
Time frame: 6 months
Tear Break up Time
Seconds required for tear film to begin to break up
Time frame: 3 months
Tear Break up Time
Seconds required for tear film to begin to break up
Time frame: 6 months
Contact Lens Fit Characteristics
Patients with substantial changes in apical clearance, limbal clearance, scleral landing evaluation
Time frame: 6 months
The subject pool consisted of patients of the Boston Sight clinic. Interested patients were directed to the principal investigator or the study coordinator, who went over the study and asked the screening questions. Recruitment occurred from February 2020 to December 2022.
| Milestone | Boost | Control |
|---|---|---|
| Started | 16 | 12 |
| Completed | 8 | 6 |
| Not completed | 8 | 6 |
LogMAR visual acuity
| logMAR visual acuity units | Boost | Control |
|---|---|---|
| Visual Acuity | 0.18 ± 0.21 | 0.17 ± 0.17 |
LogMAR visual acuity
| logMAR visual acuity units | Boost | Control |
|---|---|---|
| Visual Acuity | 0.17 ± 0.24 | 0.21 ± 0.21 |
OSDI plus additional specific questions
| OSDI score | Boost | Control |
|---|---|---|
| Contact Lens Comfort | 20.0 ± 9.9 | 19.8 ± 9.5 |
OSDI plus additional specific questions
| OSDI score | Boost | Control |
|---|---|---|
| Contact Lens Comfort | 24.7 ± 10.4 | 18.4 ± 11.6 |
Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.
| units | Boost | Control |
|---|---|---|
| Ocular Surface Staining | 2.1 ± 2.6 | 2.4 ± 2.1 |
Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.
| units | Boost | Control |
|---|---|---|
| Ocular Surface Staining | 1.9 ± 2.4 | 3.7 ± 2.3 |
Seconds required for tear film to begin to break up
| seconds | Boost | Control |
|---|---|---|
| Tear Break up Time | 4.9 ± 3.8 | 7.8 ± 4.4 |
Seconds required for tear film to begin to break up
| seconds | Boost | Control |
|---|---|---|
| Tear Break up Time | 5.6 ± 4.8 | 7.3 ± 3.9 |
Patients with substantial changes in apical clearance, limbal clearance, scleral landing evaluation
| Participants | Boost | Control |
|---|---|---|
| Contact Lens Fit Characteristics | 0 | 0 |
Collected over From enrollment until last follow-up at 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boost | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Control | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | Boost | Control |
|---|---|---|
| Lens intolerableEye disorders | 1/11 | 1/10 |
No information available for patients lost to COVID or withdrawal prior to completion of Visit 1B.
| Age, Categorical(Participants) | Boost | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 6 | 13 |
| >=65 years | 4 | 4 | 8 |
| Sex: Female, Male(Participants) | Boost | Control | Total |
|---|---|---|---|
| Female | 9 | 6 | 15 |
| Male | 2 | 4 | 6 |
| Race and Ethnicity Not Collected(Participants) | Boost | Control | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Visual Acuity(logMAR units) | Boost | Control | Total |
|---|---|---|---|
| Mean | 0.24 ± 0.19 | 0.20 ± 0.24 | 0.22 ± 0.21 |
| Contact Lens Comfort(OSDI score) | Boost | Control | Total |
|---|---|---|---|
| Mean | 22.5 ± 15.3 | 37.3 ± 19.5 | 29.6 ± 18.6 |
| Ocular Surface Staining(units) | Boost | Control | Total |
|---|---|---|---|
| Mean | 2.0 ± 3.0 | 3.5 ± 3.0 | 2.7 ± 3.1 |
| Tear break up time(seconds) | Boost | Control | Total |
|---|---|---|---|
| Mean | 7.9 ± 5.1 | 8.3 ± 4.6 | 8.1 ± 4.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Jun 2023, 39 months.
Results were first posted in Oct 2026, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.